

#33/H  
gnd  
8/28/02  
(N.E.)  
(N.E.)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans Josef Stauss

Serial No.: 09/101,413

Art Unit: 1644

Filed: August 7, 1998

Examiner: G. Ewoldt

For: "IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES"

BOX AF  
Assistant Commissioner for Patents  
Washington, D.C. 20231

## AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

Responsive to the Office Action mailed on December 11, 2001, the interview on April 11, 2002, and the Notice of Non-Compliant Amendment mailed August 9, 2002, please amend the application as follows. This amendment was being filed with an extension of time for three months time, up to and including June 11, 2002, and authorization to charge the fee for a large entity to Deposit Account No. 50-1868. The Notice of Non-Compliant Amendment provides for a response date of September 8, 2002. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-1868.

Response to Notice of Non-Compliant Amendment

Claim 1 has been amended to note that the phrase on line 1, "with a disease" has been deleted.

U.S.S.N. 09/101,413

Filed: August 7, 1998

## AMENDMENT AND RESPONSE TO OFFICE ACTION

However, claim 1 should have been amended five times upon entry of this amendment:

In the preliminary amendment filed with the application

In the amendment mailed July 19, 2000

In the amendment mailed March 28, 2001, entered upon filing a continuing prosecution application on June 12, 2001

In the amendment mailed September 28, 2001

In the amendment mailed March 11, 2002, to be entered upon filing of the continuing prosecution application May 30, 2002, replaced by this amendment

In the Claims

1. (Five times amended) A method of killing cells in a patient [with a disease characterized by expression by the patient of an abnormal antigen or an abnormally elevated amount of a antigen as compared to the non-diseased state, or by expression of an infectious agent protein], the method comprising

administering to the patient a therapeutically effective amount of cytotoxic T lymphocytes (CTL),

wherein the CTLs have a different HLA class I complex (or equivalent) than the cells to be killed, and

the CTLs specifically recognize a peptide portion on the cells to be killed of [the] (a) an abnormal antigen or (b) antigen which is abnormally elevated in the patient [patients with the disease] or (c) [the] an infectious agent protein antigen, when the peptide is presented by the

AUG.16'2002 10:54

# HOLLAND & KNIGHT LLP

One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400

404-817-8500  
FAX 404-881-0470  
http://www.hkldaw.com

**FAX RECEIVED**

AUG 16 2002

GROUP 1600

America  
Boston  
Bredenton  
Chicago  
Fort Lauderdale  
Jacksonville  
Lakeland  
Los Angeles  
Melbourne  
Miami  
New York

International Offices:  
Caracas\*  
Helsinki  
Mexico City  
Rio de Janeiro

#5329 P.001  
Northern Virginia  
Orlando  
Providence  
San Antonio  
San Francisco  
Seattle  
St. Petersburg  
Tallahassee  
Tampa  
Washington, D.C.  
West Palm Beach

Sao Paulo  
Tel Aviv  
Tokyo  
\*Representative Offices

**FACSIMILE**

OFFICIAL

**TO:**

Group 1600 After Final	Assistant Commissioner for Patents	703-872-9307
NAME	COMPANY/FIRM	FAX NUMBER
Washington	DC	703-308-0198
CITY	STATE	(TELEPHONE NUMBER)

**FROM:**

Patrea L. Pabst	404-817-8473	19
NAME	TELEPHONE	TOTAL PAGES (including Cover Sheet)

**FOR THE RECORD:**

DATE: August 7, 2002	URGENCY: <input type="checkbox"/> SUPER RUSH <input type="checkbox"/> RUSH <input type="checkbox"/> REGULAR
FAXED BY:	FILE #: 078230/00002 CLIENT NAME: RPMS 102
CONFIRMED: <input type="checkbox"/> YES <input type="checkbox"/> NO	NAME: TIME:

If you did not receive all of  
the pages or find that they  
are illegible, please call  
(404) 817-8500

**CONFIDENTIALITY NOTICE:** This facsimile, along with any documents, files, or  
attachments, may contain information that is confidential, privileged, or otherwise  
exempt from disclosure. If you are not the intended recipient or a person responsible  
for delivering it to the intended recipient, you are hereby notified that any disclosure,  
copying, printing, distribution or use of any information contained in or attached to  
this facsimile is strictly prohibited. If you have received this facsimile in error,  
please immediately notify us by facsimile or by telephone collect at the numbers  
stated above, and destroy the original facsimile and its attachments without reading,  
printing, or saving in any manner. Your cooperation is appreciated. Thank you.

**MESSAGE:**

Applicant: Hans Josef Stauss

Serial No.: 09/101,413

Art Unit: 1644

Filed: August 7, 1998

Examiner: G. Ewoldt

For: "IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES"

ATL1 #511177 v1

FAX RECEIVED

AUG 16 2002

OFFICIAL

Please type a plus sign (+) inside this box → ☐

GROUP 1600

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0861-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/101,413
	Filing Date	August 7, 1998
	First Named Inventor	Hans Josef Stauss
	Group Art Unit	1644
	Examiner Name	G. Ewoldt
Total Number of Pages in This Submission	Attorney Docket Number	RPMS 102

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Patrea L. Pabst, Reg. No. 31,284	Holland & Knight LLP
Signature	Suite 2000, One Atlantic Center; 1201 West Peachtree Street, N.E.; Atlanta, GA 30309-3400	
Date	August 16, 2002	

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: _____		
Typed or printed name	SEE CERTIFICATE OF FACSIMILE TRANSMITTAL	
Signature		Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/17 (11-01)

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL**  
**for FY 2002**

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) -0-

**Complete if Known**

Application Number	09/101,413
Filing Date	August 7, 1998
First Named Inventor	Hans Josef Stauss
Examiner Name	G. Ewoldt
Group Art Unit	1644
Attorney Docket No.	RPMS 102

**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit  
Account  
Number  
Deposit  
Account  
Name

50-1868

Holland &amp; Knight LLP

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☐ Charge any additional fee(s) during the pendency of this application  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.
**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
101 740	201 370	Utility filing fee	
108 330	206 165	Design filing fee	
107 510	207 255	Plant filing fee	
108 740	208 370	Reissue filing fee	
114 180	214 80	Provisional filing fee	

SUBTOTAL (1) (\$)

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims	Extra Claims	Fee from below	Fee Paid
18	20	0	0
1	3	0	0

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
103 18	203 9	Claims in excess of 20	
102 84	202 42	Independent claims in excess of 3	
104 280	204 140	Multiple dependent claim, if not paid	
109 84	209 42	** Reissue independent claims over original patent	
110 18	210 9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$) -0-

\*\*or number previously paid, if greater; For Reissues, 50% above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Small Entity

Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
106 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
138 130	139 130	Non-English specification	
147 2,620	147 2,620	For filing a request for ex parte reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 65	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	
118 1,440	218 720	Extension for reply within fourth month	
128 1,960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(a)	
128 180	128 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
148 740	248 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
178 740	278 370	Request for Continued Examination (RCE)	
169 800	169 800	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

**SUBMITTED BY**

Name (Print/Type)

Patricia L. Pabst

Registration No.  
(Attorney/Agent)

31,284

**Complete if applicable**

Telephone

(404) 817-8473

Signature

Date

August 16, 2002

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Received from &lt; &gt; at 8/16/02 11:10:57 AM [Eastern Daylight Time]

U.S.S.N. 09/101,413  
Filed August 7, 1998  
AMENDMENT AND RESPONSE TO OFFICE ACTION

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that the attached AMENDMENT AND RESPONSE TO OFFICE ACTION  
and all documents shown as being attached is being facsimile transmitted to the U. S. Patent and  
Trademark Office on the date shown below.

Date: August 16, 2002

  
\_\_\_\_\_  
Jean Hicks

ATL1 #539606 v1

RPMS 102  
078230/00002